Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Nisin is a bacteriocin, a type of antimicrobial peptide produced by the bacterium Lactococcus lactis. Its primary use has been as a food preservative due to its effectiveness against a range of Gram-positive bacteria, including Staphylococcus aureus (the causative agent of many staph infections). Several in vitro studies have demonstrated that nisin can inhibit the growth of S. aureus, including methicillin-resistant strains (MRSA). The mechanism involves disrupting the bacterial cell wall by binding to lipid II, an essential component in the synthesis of peptidoglycan. Although these laboratory results are promising, clinical evidence for the use of nisin in treating or supporting staph infections in humans is limited. Most research to date has been conducted in vitro or in animal models. There are a few preclinical studies suggesting that nisin formulations can reduce bacterial load and infection severity in animal skin infection models. However, robust human clinical trials are lacking. In summary, the scientific rationale and laboratory evidence for nisin's anti-staphylococcal activity are substantial, justifying a moderate evidence rating. Nevertheless, the absence of comprehensive human clinical trial data prevents a higher rating. Nisin is not a standard or approved therapeutic agent for staph infections in clinical medicine, but it remains an area of ongoing research.

More about Nisin
More about Staph Infections

Other ingredients used for Staph Infections

Other health conditions supported by Nisin

Products containing Nisin